Boehringer Ingelheim

Cellares Appoints John Tomtishen as Vice President of Operations

Retrieved on: 
Monday, October 11, 2021
GMP, BLA, SAN, Engineering, Legend, Janssen Pharmaceuticals, Time, Marketing, Software, Boehringer Ingelheim, File, CMC, Maintenance, Vaccine, Horizon Fuel Cell Technologies, Therapy, Site management organization, Partnership, Patient, Global marketing, Technology, Novartis, Pharmaceutical industry, Food preservation, Management, Fine chemical

"John's deep experience manufacturing multiple cell therapies will ensure seamless integration of our technology into our customers' manufacturing processes, today and in the future -- in particular as we begin to revolutionize manufacturing of these life-saving medicines," said Fabian Gerlinghaus, Chief Executive Officer, Cellares. "We are delighted to welcome John to the team."

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Oct. 11, 2021 /PRNewswire/ --Cellares Corporation, a life sciences technology company pioneering a revolutionary automated approach to cell therapy manufacturing, today announced the appointment of John Tomtishen as Vice President of Operations.
  • Mr. Tomtishen has more than 10 years of experience within cell and gene therapies, biologics, and vaccines, and has held diverse roles in business operations, CMC/technical operations, engineering and facilities, and supply chain operations.
  • In his new role at Cellares, Mr. Tomtishen will be responsible for supporting partnership activities and facilitating accelerated market adoption of Cellares' Cell Shuttle technology.
  • Previously, Mr. Tomtishen owned and managed technical operations for Novartis' cell and gene therapy products, from late-stage clinical development through commercial lifecycle management.

OSE Immunotherapeutics Receives New European Patent Notice of Allowance for Tedopi®

Retrieved on: 
Monday, October 11, 2021
ISIN, IL-7, Patent, Large-cell lung carcinoma, Mab, Non-small-cell lung carcinoma, Degenerative disease, Veloxis Pharmaceuticals, Inflammation, B cell, European Patent Office, OSE, COVID-19, ESMO, Mnemos EP, Tissue, NSCLC, Failure, Macrophage, GLOBE, Nivolumab, Boehringer Ingelheim, European Society for Medical Oncology, Cancer, Fortification, Vaccination, Immunotherapy, Immune system, European Patent Convention, Severe acute respiratory syndrome coronavirus 2, Ulcerative colitis, Oncology, Congress, Patient, ICIS, Partnership, PD-1, Research, Pancreatic cancer, Autoimmune disease, Epitope, Pharmaceutical industry, Fine chemical, Vaccine

This new patent notice of allowance granted in Europe reinforces the patent protection for Tedopi and confirms an optimized industrial manufacturing process using a ready-to-use peptide emulsion.

Key Points: 
  • This new patent notice of allowance granted in Europe reinforces the patent protection for Tedopi and confirms an optimized industrial manufacturing process using a ready-to-use peptide emulsion.
  • Tedopi has shown positive final results from the Atalante 1 Phase 3 study in non-small cell lung patients after secondary resistance to immune checkpoint inhibitors (presented at the 2021 ESMO (European Society for Medical Oncology) Congress ).
  • Such combinations will further reinforce the therapeutic value of Tedopi in late-stage cancer indications.
  • OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases.

Mogrify Strengthens Executive Leadership Team with the Appointment of Louise Modis as Chief Scientific Officer

Retrieved on: 
Tuesday, October 5, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Boehringer Ingelheim, Degenerative disease, Research, USD, Bachelor of Science, Harvard University, National university, GSK, EMBL, Patient, National University of Ireland, CEO, Limited, Immunology, Ophthalmology, OBE, GlaxoSmithKline, Biotechnology, Allergy, Asthma & Immunology Research, Drug discovery, Takeda Oncology, Pharmaceutical industry, Medical imaging

Louise is an accomplished scientific leader in therapeutic discovery and development, and holds considerable experience in the progression of pre-clinical and clinical-stage assets, across various modalities and therapeutic areas.

Key Points: 
  • Louise is an accomplished scientific leader in therapeutic discovery and development, and holds considerable experience in the progression of pre-clinical and clinical-stage assets, across various modalities and therapeutic areas.
  • In her new role, Louise will lead the advancement of the Companys internal programs to help address high unmet clinical need in ophthalmology, immuno-oncology and other disease areas.
  • Dr. Darrin M. Disley, OBE, CEO, Mogrify, said: We are delighted to welcome Louise to the Mogrify Executive Team following a global search that considered drug discovery specialists from across Europe and the United States.
  • Dr. Louise Modis, Chief Scientific Officer, Mogrify, added: I am very excited to join Mogrify and to be able to deploy its powerful cell reprogramming platform to address the most immediate challenges of developing cost-effective ex vivo cell therapies in immuno-oncology.

Ready for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-Metabolic Conditions for Healthcare Professionals

Retrieved on: 
Monday, October 4, 2021
Type 2 diabetes, Animal Health, Boehringer Ingelheim, Death, Department of Medicine – University of Pamplona, Program, Disease management, Insulin, American Diabetes Association, Chronic kidney disease, Heart failure, Degenerative disease, Animal, Research, Health, Physician, Heart, Kidney, Diabetes, Twitter, CA, Knowledge, Awareness, Disease, Facebook, Duke University School of Medicine, NYSE, Medical Affairs Bureau, LLY, Partnership, Psychological warfare, Eli Lilly and Company, Risk, Corporate social responsibility, Human, D, HCP, Department, Adoption, Marketing, Cardiology, American College of Cardiology, HCPS, Animation, Patient, American Association of Clinical Endocrinologists, Ownership, Boehringer Ingelheim Animal Health, Quality of life, Nephrology, Pharmaceutical industry, Medicine, Sales, Fine chemical

"The recent improvements in C-R-M care have empowered generalists and specialists to take ownership over these connected conditions.

Key Points: 
  • "The recent improvements in C-R-M care have empowered generalists and specialists to take ownership over these connected conditions.
  • Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation and is part of the Boehringer Ingelheim group of companies.
  • In addition, there are Boehringer Ingelheim Animal Health in Duluth, GA and Boehringer Ingelheim Fremont, Inc. in Fremont, CA.
  • Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world.

Boehringer Ingelheim and OSE Immunotherapeutics Announce First Patient Dosed in Phase 1 Expansion Trial of SIRPα Antagonist Monoclonal Antibody BI 765063 in combination with anti-PD-1 Antibody Ezabenlimab, in Patients with Advanced Endometrium or Colore

Retrieved on: 
Thursday, September 30, 2021
ISIN, CD47, Standard of care, Pancreatic cancer, Clinical trial, Endometrium, Safety, ESMO, Veloxis Pharmaceuticals, Step, Macrophage, OSE, Degenerative disease, MSS, Inflammation, IL-7, Immune system, Mab, Disease, Ulcerative colitis, Boehringer Ingelheim, Vaccination, Neoplasm, Index (publishing), Partnership, Patient, Mnemos EP, Epitope, Toxicity, PD-1, Large-cell lung carcinoma, Fortification, Cancer, Myelocyte, Severe acute respiratory syndrome coronavirus 2, Tissue, B cell, Autoimmune disease, BI, GLOBE, MTD, Immunotherapy, ASCO, COVID-19, Nivolumab, Research, Colorectal cancer, Pharmaceutical industry, Vaccine, Fine chemical

Dosing of first patient in the expansion phase triggers a milestone payment of 8 million from Boehringer Ingelheim to OSE Immunotherapeutics.

Key Points: 
  • Dosing of first patient in the expansion phase triggers a milestone payment of 8 million from Boehringer Ingelheim to OSE Immunotherapeutics.
  • BI 765063 is a first-in-class SIRP inhibitor on the CD47/ SIRP Dont eat me pathway being developed under collaborative agreement between OSE Immunotherapeutics and Boehringer Ingelheim.
  • The dose escalation part of the Phase 1 trial (Step 1), evaluating BI 765063 alone and in combination with ezabenlimab, has been completed with a total of 18 patients enrolled in combination.
  • BI 765063 is a monoclonal antibody antagonist of the key myeloid cell checkpoint inhibitor SIRP.

Total number of shares and voting rights in Zealand Pharma at September 30, 2021

Retrieved on: 
Thursday, September 30, 2021
Diabetes, Hypoglycemia, Patient, Nasdaq, Adult, Zealand Pharma, AstraZeneca, Boehringer Ingelheim, Pharmaceutical industry

Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of peptide-based medicines.

Key Points: 
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of peptide-based medicines.
  • More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development.
  • The above information contains forward-looking statements that provide Zealand Pharmas expectations or forecasts of future events.
  • All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.

Inflammasome Therapeutics’ Kamuvudines Continue to Show Promise for Future Treatment – and Potentially a Cure – for Blindness in Seniors

Retrieved on: 
Thursday, September 30, 2021
Science, Other Science, Research, Optical, General Health, Health, Clinical Trials, Other Health, Retina, Rest, Geographic atrophy, Severe cognitive impairment, Degenerative disease, Intravitreal injection, University, Ageing, III, RPE, AMD, Population, Toxicity, A-DNA, Bill, CEO, MS, Center, Disease, Boehringer Ingelheim, HIV disease progression rates, Human, View, Research, Bill & Melinda Gates Foundation, Cell, Pharmaceutical industry

It has been previously reported that Alu RNA is over expressed in the retinas of individuals with this condition.

Key Points: 
  • It has been previously reported that Alu RNA is over expressed in the retinas of individuals with this condition.
  • The paper confirms that in human eyes Alu RNA/cDNA conversion triggers inflammasome activity and resulting retinal cell death.
  • Additionally, we continue to strengthen the body of peer-reviewed science that demonstrates NRTIs and Kamuvudines ability to inhibit inflammasome activation.
  • Dr. Ashton said that Inflammasome plans to bring one or more of its Kamuvudines into the clinic in 2022.

Lifebit raises $60m to make vital biomedical data securely accessible for life changing research worldwide

Retrieved on: 
Wednesday, September 29, 2021
Partnership, Internet, Software, Precision medicine, Genomics England, Beacon Capital Partners, Tiger Global Management, Growth, Technology, Drug discovery, Contract, Databricks, Investment, Boehringer Ingelheim, UK, Medical device

Unlocking access to biomedical data has the power to rid society of its most devastating diseases.

Key Points: 
  • Unlocking access to biomedical data has the power to rid society of its most devastating diseases.
  • Yet despite the rapid growth of biomedical data in recent years, only a fraction of it is being utilised for drug discovery and precision medicine.
  • Lifebit builds enterprise data platforms for use by organisations with complex and sensitive biomedical datasets.
  • This patented technology solves the biggest roadblock for precision medicine - making highly sensitive biomedical data securely accessible by bringing researchers' analysis and computation to where data resides, instead of moving data around.

Lifebit raises $60m to make vital biomedical data securely accessible for life changing research worldwide

Retrieved on: 
Wednesday, September 29, 2021
Partnership, Internet, Software, Precision medicine, Genomics England, Beacon Capital Partners, Tiger Global Management, Growth, Technology, Drug discovery, Contract, Databricks, Investment, Boehringer Ingelheim, UK, Medical device

Unlocking access to biomedical data has the power to rid society of its most devastating diseases.

Key Points: 
  • Unlocking access to biomedical data has the power to rid society of its most devastating diseases.
  • Yet despite the rapid growth of biomedical data in recent years, only a fraction of it is being utilised for drug discovery and precision medicine.
  • Lifebit builds enterprise data platforms for use by organisations with complex and sensitive biomedical datasets.
  • This patented technology solves the biggest roadblock for precision medicine - making highly sensitive biomedical data securely accessible by bringing researchers' analysis and computation to where data resides, instead of moving data around.

Heart Experts Call For Millions To Benefit From Life-Saving Online Services As Telemedicine Rockets

Retrieved on: 
Tuesday, September 28, 2021
Blood pressure, Policy, Telehealth, Diagnosis, Health, World Heart Federation, WHF, Patient, Population, Cardiovascular disease, CVD, AstraZeneca, Boehringer Ingelheim, COVID-19, Pfizer, Cardiology, Industry, Automated ECG interpretation, Pharmaceutical industry

GENEVA, Sept. 28, 2021 /PRNewswire/ -- On World Heart Day, 29 September 2021, the World Heart Federation (WHF) is calling on the international community to bring digital cardiovascular health services to millions worldwide. COVID-19 has seen an explosion in telemedicine, with a 40%1 jump in the world's richest countries. WHF believes this digital transformation presents a pivotal opportunity for millions living with cardiovascular disease from lower-income backgrounds who have little access to in-person consultation.

Key Points: 
  • COVID-19 has seen an explosion in telemedicine, with a 40%1 jump in the world's richest countries.
  • WHF believes this digital transformation presents a pivotal opportunity for millions living with cardiovascular disease from lower-income backgrounds who have little access to in-person consultation.
  • "Never before have we seen such a 'techceleration' in cardiology," says Fausto Pinto, President of the World Heart Federation.
  • The general public is encouraged to get involved in World Heart Day by joining the conversation across social platforms using the hashtags #UseHeart and #WorldHeartDay.